Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

Abstract Background Triple negative breast cancer (TNBC) represents 15–20% of breast cancers. Due to its heterogeneity and high rates of relapse, there is a need to optimize treatment efficacy. Platinum chemotherapy is still controversial and currently not recommended as first-line treatment for TNB...

Full description

Bibliographic Details
Main Authors: Jessa Gilda P. Pandy, Joanmarie C. Balolong-Garcia, Mel Valerie B. Cruz-Ordinario, Frances Victoria F. Que
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Cancer
Subjects:
Triple negative breast cancer
Platinum chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-019-6253-5

Internet

http://link.springer.com/article/10.1186/s12885-019-6253-5

Similar Items